Table of Contents
PITTSBURGH — Mylan N.V. this week introduced two new generic drugs in the U.S. market.
On Monday, the company announced final Food and Drug Administration approval for dextroamphetamine sulfate extended-release capsules — in dosages of 5 mg, 10 mg and 15 mg — and finasteride tablets 1 mg.
Mylan’s dextroamphetamine sulfate ER capsules are a generic version of Amedra Pharmaceuticals’s Dexedrine, a treatment for narcolepsy and attention deficit disorder with hyperactivity, and its finasteride product is a generic version of Merck’s Propecia, used for the treatment of pattern hair loss in men.
U.S. sales for the 12 months ended May 31 totaled $101.3 million for dextroamphetamine sulfate ER capsules (5 mg, 10 mg and 15 mg) and $35.3 million for finasteride tablets (1 mg), according to IMS Health data reported by Mylan.
